Progress in the application of molecular testing in the diagnosis and treatment of thyroid cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

ZHANG Yajing ¹ , DENG Juan ² , LUO Si ² ,  TANG Yuan ¹

1. Department of Pathology, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;
2. Shanghai RIGEN Biotechnology Co., Ltd., Shanghai 200237, P. R. China;

Corresponding?author：

TANG Yuan, Email: 1202ty@163.com

Keywords：

thyroid cancer; molecular testing; molecular risk stratification; targeted therapy; precision medicine

DOI：

10.7507/1007-9424.202509089

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summarize the recent advances and clinical applications of molecular testing in thyroid cancer, discussing its significance in the era of precision medicine and future perspectives. Methods A systematic review of relevant domestic and international literature was conducted to identify key molecular events closely associated with the development, progression, and prognosis of thyroid cancer, and to evaluate their clinical utility. Results Molecular testing provides critical auxiliary diagnostic information for thyroid nodules with indeterminate fine-needle aspiration results. Furthermore, for diagnosed differentiated thyroid cancer, molecular markers serve as important tools for precise risk stratification, guiding surgical extent, radioactive iodine therapy decisions, and targeted drug applications. Conclusion Molecular testing has become a cornerstone tool in advancing thyroid cancer management toward precision medicine, future efforts should focus on exploring novel molecular markers and optimizing clinical practice guidelines.

Citation： ZHANG Yajing, DENG Juan, LUO Si, TANG Yuan. Progress in the application of molecular testing in the diagnosis and treatment of thyroid cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2025, 32(10): 1285-1290. doi: 10.7507/1007-9424.202509089 Copy

1.	Ali SZ, Baloch ZW, Cochand-Priollet B, et al. The 2023 Bethesda system for reporting thyroid cytopathology. Thyroid, 2023, 33(9): 1039-1044.
2.	殷德濤, 趙乾. 全球及中國甲狀腺癌的發病特征及趨勢. 中國普外基礎與臨床雜志, 2025, 32(6): 687-693.
3.	何林燁, 王藝超, 李志輝. 2022年中國甲狀腺癌流行情況分析: 基于《中國腫瘤登記年報》2005-2018年數據. 中國普外基礎與臨床雜志, 2024, 31(7): 790-795.
4.	Du L, Li R, Ge M, et al. Incidence and mortality of thyroid cancer in China, 2008-2012. Chin J Cancer Res, 2019, 31(1): 144-151.
5.	Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent, 2024, 4(1): 47-53.
6.	Zeng H, Zheng R, Sun K, et al. Cancer survival statistics in China 2019-2021: a multicenter, population-based study. J Natl Cancer Cent, 2024, 4(3): 203-213.
7.	Valderrabano P, Eszlinger M, Stewardson P, et al. Clinical value of molecular markers as diagnostic and prognostic tools to guide treatment of thyroid cancer. Clin Endocrinol (Oxf), 2023, 98(6): 753-762.
8.	Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell, 2014, 159(3): 676-690.
9.	Ringel MD, Sosa JA, Baloch Z, et al. 2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid cancer. Thyroid, 2025, 35(8): 841-985.
10.	Moulana FI, Priyani AAH, de Silva MVC, et al. BRAF-oncogene-induced senescence and the role of thyroid-stimulating hormone signaling in the progression of papillary thyroid carcinoma. Horm Cancer, 2018, 9(1): 1-11.
11.	Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol, 2011, 7(10): 569-580.
12.	Karimi AH, Zeng PY, Cecchini M, et al. Novel insights in advanced thyroid carcinoma: from mechanisms to treatments: molecular insights into the origin, biology, and treatment of anaplastic thyroid carcinoma. Eur Thyroid J, 2025, 14(3): e250057. doi: 10.1530/ETJ-25-0057.
13.	Jeong SH, Hong HS, Lee EH, et al. Analysis of RAS mutation in thyroid nodular hyperplasia and follicular neoplasm in a Korean population. Endocrinol Diabetes Metab, 2018, 1(4): e00040. doi: 10.1002/edm2.40.
14.	Howell GM, Hodak SP, Yip L. RAS mutations in thyroid cancer. Oncologist, 2013, 18(8): 926-932.
15.	Zhang Y, Zheng WH, Zhou SH, et al. Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives. Cell Commun Signal, 2024, 22(1): 460. doi: 10.1186/s12964-024-01837-x.
16.	Landa I, Cabanillas ME. Genomic alterations in thyroid cancer: biological and clinical insights. Nat Rev Endocrinol, 2024, 20(2): 93-110.
17.	Yip L, Ferris RL. Clinical application of molecular testing of fine-needle aspiration specimens in thyroid nodules. Otolaryngol Clin North Am, 2014, 47(4): 557-571.
18.	Cha YJ, Koo JS. Next-generation sequencing in thyroid cancer. J Transl Med, 2016, 14(1): 322. doi: 10.1186/s12967-016-1074-7.
19.	Schumm MA, Shu ML, Hughes EG, et al. Prognostic value of preoperative molecular testing and implications for initial surgical management in thyroid nodules harboring suspected (Bethesda Ⅴ) or known (Bethesda Ⅵ) papillary thyroid cancer. JAMA Otolaryngol Head Neck Surg, 2023, 149(8): 735-742.
20.	Livhits MJ, Zhu CY, Kuo EJ, et al. Effectiveness of molecular testing techniques for diagnosis of indeterminate thyroid nodules: a randomized clinical trial. JAMA Oncol, 2021, 7(1): 70-77.
21.	Patel J, Klopper J, Cottrill EE. Molecular diagnostics in the evaluation of thyroid nodules: current use and prospective opportunities. Front Endocrinol (Lausanne), 2023, 14: 1101410. doi: 10.3389/fendo.2023.1101410.
22.	Mete O, Boucher A, Schrader KA, et al. Consensus statement: recommendations on actionable biomarker testing for thyroid cancer management. Endocr Pathol, 2024, 35(4): 293-308.
23.	Najafian A, Noureldine S, Azar F, et al. RAS mutations, and RET/PTC and PAX8/PPAR-gamma chromosomal rearrangements are also prevalent in benign thyroid lesions: implications thereof and a systematic review. Thyroid, 2017, 27(1): 39-48.
24.	Ding M, Wu G, Zhang S, et al. Clinical implications and application of molecular testing in the diagnosis and management of thyroid nodules in the Chinese population. Clin Cancer Res, 2025. doi: 10.1158/1078-0432.CCR-25-0270.
25.	WHO classification of tumours editorial board. Endocrine and neuroendocrine tumours. WHO classification of tumours (5th ed), Lyon, France: WHO/IARC Press.
26.	Zhao H, Zhang ZH, Zhou B, et al. Detection of BRAF c. 1799T>A (p. V600E) mutation using residual routine fine-needle aspiration specimens of papillary thyroid carcinoma. Diagn Cytopathol, 2015, 43(10): 786-790.
27.	Chen H, Song A, Wang Y, et al. BRAF V600E mutation test on fine-needle aspiration specimens of thyroid nodules: clinical correlations for 4 600 patients. Cancer Med, 2022, 11(1): 40-49.
28.	Zhang YZ, Xu T, Cui D, et al. Value of TIRADS, BSRTC and FNA-BRAF V600E mutation analysis in differentiating high-risk thyroid nodules. Sci Rep, 2015, 5: 16927. doi: 10.1038/srep16927.
29.	張亞麗, 王冬青, 張賀, 等. 大樣本評價BRAF V600E基因檢測在甲狀腺細胞學診斷中的價值. 中華病理學雜志, 2020, 49(2): 186-188.
30.	管文燕, 鄭金榆, 聶嶺, 等. 基因檢測在甲狀腺結節診斷中分層應用模式的研究. 中華病理學雜志, 2024, 53(3): 264-268.
31.	甲狀腺細針穿刺細胞病理學診斷專家共識編寫組, 中華醫學會病理學分會細胞病理學組. 甲狀腺細針穿刺細胞病理學診斷專家共識 (2023版). 中華病理學雜志, 2023, 52(5): 441-446.
32.	Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol, 2016, 2(8): 1023-1029.
33.	Nikiforov YE, Baloch ZW, Hodak SP, et al. Change in diagnostic criteria for noninvasive follicular thyroid neoplasm with papillarylike nuclear features. JAMA Oncol, 2018, 4(8): 1125-1126.
34.	廣東省醫學教育協會甲狀腺專業委員會, 廣東省基層醫藥學會細胞病理與分子診斷專業委員會. 甲狀腺癌基因檢測與臨床應用廣東專家共識 (2020版). 中華普通外科學文獻 (電子版), 2020, 14(3): 161-168.
35.	中國臨床腫瘤學會指南工作委員會. 中國臨床腫瘤學會 (CSCO) 分化型甲狀腺癌診療指南2021. 腫瘤預防與治療, 2021, 34(12): 1164-1200.
36.	中華醫學會內分泌學分會, 中華醫學會外科學分會甲狀腺及代謝外科學組, 中國抗癌協會頭頸腫瘤專業委員會, 等. 甲狀腺結節和分化型甲狀腺癌診治指南 (第二版). 中華內分泌代謝雜志, 2023, 39(3): 181-226.
37.	Mauri G, Hegedüs L, Bandula S, et al. European Thyroid Association and Cardiovascular and Interventional Radiological Society of Europe 2021 clinical practice guideline for the use of minimally invasive treatments in malignant thyroid lesions. Eur Thyroid J, 2021, 10(3): 185-197.
38.	Liu J, Liu R, Shen X, et al. The genetic duet of BRAF V600E and TERT promoter mutations robustly predicts loss of radioiodine avidity in recurrent papillary thyroid cancer. J Nucl Med, 2020, 61(2): 177-182.
39.	Ho AL, Grewal RK, Leboeuf R, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med, 2013, 368(7): 623-632.
40.	中國臨床腫瘤學會核醫學專家委員會, 中國臨床腫瘤學會甲狀腺癌專家委員會, 中華醫學會核醫學分會, 等. 放射性碘難治性分化型甲狀腺癌診治管理指南 (2024版). 中華核醫學與分子影像雜志, 2024, 44(6): 359-372.
41.	Rothenberg SM, McFadden DG, Palmer EL, et al. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. Clin Cancer Res, 2015, 21(5): 1028-1035.
42.	Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase Ⅱ ROAR basket study. Ann Oncol, 2022, 33(4): 406-415.
43.	Paspala A, Bompetsi G, Paschou SA, et al. The value of preoperative molecular testing in the management of Bethesda Ⅴ and Bethesda Ⅵ thyroid tumors. Hormones (Athens), 2025, 24(1): 217-229.
44.	Xing M, Liu R, Liu X, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol, 2014, 32(25): 2718-2726.
45.	Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid Cancer. Thyroid, 2016, 26(1): 1-133.
46.	Liu J, Gao W, Zheng X, et al. Molecular testing stratifies the risk of structural recurrence in high risk differentiated thyroid cancer: a retrospective cohort study. Front Endocrinol (Lausanne), 2025, 16: 1508404. doi: 10.3389/fendo.2025.1508404.
47.	廣東省醫學教育協會甲狀腺專業委員會, 廣東省基層醫藥學會細胞病理與分子診斷專業委員會. 甲狀腺癌RET基因檢測與臨床應用專家共識 (2021版). 中華普通外科學文獻 (電子版), 2022, 16(1): 1-8.
48.	中國醫師協會外科醫師分會甲狀腺外科醫師委員會, 中國抗癌協會甲狀腺癌專業委員會, 中國研究型醫院學會甲狀腺疾病專業委員會. 甲狀腺髓樣癌診斷與治療中國專家共識 (2020版). 中國實用外科雜志, 2020, 40(9): 1012-1020.
49.	Wells SA, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid, 2015, 25(6): 567-610.
50.	Castinetti F, Waguespack SG, Machens A, et al. Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study. Lancet Diabetes Endocrinol, 2019, 7(3): 213-220.

1. Ali SZ, Baloch ZW, Cochand-Priollet B, et al. The 2023 Bethesda system for reporting thyroid cytopathology. Thyroid, 2023, 33(9): 1039-1044.
2. 殷德濤, 趙乾. 全球及中國甲狀腺癌的發病特征及趨勢. 中國普外基礎與臨床雜志, 2025, 32(6): 687-693.
3. 何林燁, 王藝超, 李志輝. 2022年中國甲狀腺癌流行情況分析: 基于《中國腫瘤登記年報》2005-2018年數據. 中國普外基礎與臨床雜志, 2024, 31(7): 790-795.
4. Du L, Li R, Ge M, et al. Incidence and mortality of thyroid cancer in China, 2008-2012. Chin J Cancer Res, 2019, 31(1): 144-151.
5. Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent, 2024, 4(1): 47-53.
6. Zeng H, Zheng R, Sun K, et al. Cancer survival statistics in China 2019-2021: a multicenter, population-based study. J Natl Cancer Cent, 2024, 4(3): 203-213.
7. Valderrabano P, Eszlinger M, Stewardson P, et al. Clinical value of molecular markers as diagnostic and prognostic tools to guide treatment of thyroid cancer. Clin Endocrinol (Oxf), 2023, 98(6): 753-762.
8. Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell, 2014, 159(3): 676-690.
9. Ringel MD, Sosa JA, Baloch Z, et al. 2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid cancer. Thyroid, 2025, 35(8): 841-985.
10. Moulana FI, Priyani AAH, de Silva MVC, et al. BRAF-oncogene-induced senescence and the role of thyroid-stimulating hormone signaling in the progression of papillary thyroid carcinoma. Horm Cancer, 2018, 9(1): 1-11.
11. Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol, 2011, 7(10): 569-580.
12. Karimi AH, Zeng PY, Cecchini M, et al. Novel insights in advanced thyroid carcinoma: from mechanisms to treatments: molecular insights into the origin, biology, and treatment of anaplastic thyroid carcinoma. Eur Thyroid J, 2025, 14(3): e250057. doi: 10.1530/ETJ-25-0057.
13. Jeong SH, Hong HS, Lee EH, et al. Analysis of RAS mutation in thyroid nodular hyperplasia and follicular neoplasm in a Korean population. Endocrinol Diabetes Metab, 2018, 1(4): e00040. doi: 10.1002/edm2.40.
14. Howell GM, Hodak SP, Yip L. RAS mutations in thyroid cancer. Oncologist, 2013, 18(8): 926-932.
15. Zhang Y, Zheng WH, Zhou SH, et al. Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives. Cell Commun Signal, 2024, 22(1): 460. doi: 10.1186/s12964-024-01837-x.
16. Landa I, Cabanillas ME. Genomic alterations in thyroid cancer: biological and clinical insights. Nat Rev Endocrinol, 2024, 20(2): 93-110.
17. Yip L, Ferris RL. Clinical application of molecular testing of fine-needle aspiration specimens in thyroid nodules. Otolaryngol Clin North Am, 2014, 47(4): 557-571.
18. Cha YJ, Koo JS. Next-generation sequencing in thyroid cancer. J Transl Med, 2016, 14(1): 322. doi: 10.1186/s12967-016-1074-7.
19. Schumm MA, Shu ML, Hughes EG, et al. Prognostic value of preoperative molecular testing and implications for initial surgical management in thyroid nodules harboring suspected (Bethesda Ⅴ) or known (Bethesda Ⅵ) papillary thyroid cancer. JAMA Otolaryngol Head Neck Surg, 2023, 149(8): 735-742.
20. Livhits MJ, Zhu CY, Kuo EJ, et al. Effectiveness of molecular testing techniques for diagnosis of indeterminate thyroid nodules: a randomized clinical trial. JAMA Oncol, 2021, 7(1): 70-77.
21. Patel J, Klopper J, Cottrill EE. Molecular diagnostics in the evaluation of thyroid nodules: current use and prospective opportunities. Front Endocrinol (Lausanne), 2023, 14: 1101410. doi: 10.3389/fendo.2023.1101410.
22. Mete O, Boucher A, Schrader KA, et al. Consensus statement: recommendations on actionable biomarker testing for thyroid cancer management. Endocr Pathol, 2024, 35(4): 293-308.
23. Najafian A, Noureldine S, Azar F, et al. RAS mutations, and RET/PTC and PAX8/PPAR-gamma chromosomal rearrangements are also prevalent in benign thyroid lesions: implications thereof and a systematic review. Thyroid, 2017, 27(1): 39-48.
24. Ding M, Wu G, Zhang S, et al. Clinical implications and application of molecular testing in the diagnosis and management of thyroid nodules in the Chinese population. Clin Cancer Res, 2025. doi: 10.1158/1078-0432.CCR-25-0270.
25. WHO classification of tumours editorial board. Endocrine and neuroendocrine tumours. WHO classification of tumours (5th ed), Lyon, France: WHO/IARC Press.
26. Zhao H, Zhang ZH, Zhou B, et al. Detection of BRAF c. 1799T>A (p. V600E) mutation using residual routine fine-needle aspiration specimens of papillary thyroid carcinoma. Diagn Cytopathol, 2015, 43(10): 786-790.
27. Chen H, Song A, Wang Y, et al. BRAF V600E mutation test on fine-needle aspiration specimens of thyroid nodules: clinical correlations for 4 600 patients. Cancer Med, 2022, 11(1): 40-49.
28. Zhang YZ, Xu T, Cui D, et al. Value of TIRADS, BSRTC and FNA-BRAF V600E mutation analysis in differentiating high-risk thyroid nodules. Sci Rep, 2015, 5: 16927. doi: 10.1038/srep16927.
29. 張亞麗, 王冬青, 張賀, 等. 大樣本評價BRAF V600E基因檢測在甲狀腺細胞學診斷中的價值. 中華病理學雜志, 2020, 49(2): 186-188.
30. 管文燕, 鄭金榆, 聶嶺, 等. 基因檢測在甲狀腺結節診斷中分層應用模式的研究. 中華病理學雜志, 2024, 53(3): 264-268.
31. 甲狀腺細針穿刺細胞病理學診斷專家共識編寫組, 中華醫學會病理學分會細胞病理學組. 甲狀腺細針穿刺細胞病理學診斷專家共識 (2023版). 中華病理學雜志, 2023, 52(5): 441-446.
32. Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol, 2016, 2(8): 1023-1029.
33. Nikiforov YE, Baloch ZW, Hodak SP, et al. Change in diagnostic criteria for noninvasive follicular thyroid neoplasm with papillarylike nuclear features. JAMA Oncol, 2018, 4(8): 1125-1126.
34. 廣東省醫學教育協會甲狀腺專業委員會, 廣東省基層醫藥學會細胞病理與分子診斷專業委員會. 甲狀腺癌基因檢測與臨床應用廣東專家共識 (2020版). 中華普通外科學文獻 (電子版), 2020, 14(3): 161-168.
35. 中國臨床腫瘤學會指南工作委員會. 中國臨床腫瘤學會 (CSCO) 分化型甲狀腺癌診療指南2021. 腫瘤預防與治療, 2021, 34(12): 1164-1200.
36. 中華醫學會內分泌學分會, 中華醫學會外科學分會甲狀腺及代謝外科學組, 中國抗癌協會頭頸腫瘤專業委員會, 等. 甲狀腺結節和分化型甲狀腺癌診治指南 (第二版). 中華內分泌代謝雜志, 2023, 39(3): 181-226.
37. Mauri G, Hegedüs L, Bandula S, et al. European Thyroid Association and Cardiovascular and Interventional Radiological Society of Europe 2021 clinical practice guideline for the use of minimally invasive treatments in malignant thyroid lesions. Eur Thyroid J, 2021, 10(3): 185-197.
38. Liu J, Liu R, Shen X, et al. The genetic duet of BRAF V600E and TERT promoter mutations robustly predicts loss of radioiodine avidity in recurrent papillary thyroid cancer. J Nucl Med, 2020, 61(2): 177-182.
39. Ho AL, Grewal RK, Leboeuf R, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med, 2013, 368(7): 623-632.
40. 中國臨床腫瘤學會核醫學專家委員會, 中國臨床腫瘤學會甲狀腺癌專家委員會, 中華醫學會核醫學分會, 等. 放射性碘難治性分化型甲狀腺癌診治管理指南 (2024版). 中華核醫學與分子影像雜志, 2024, 44(6): 359-372.
41. Rothenberg SM, McFadden DG, Palmer EL, et al. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. Clin Cancer Res, 2015, 21(5): 1028-1035.
42. Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase Ⅱ ROAR basket study. Ann Oncol, 2022, 33(4): 406-415.
43. Paspala A, Bompetsi G, Paschou SA, et al. The value of preoperative molecular testing in the management of Bethesda Ⅴ and Bethesda Ⅵ thyroid tumors. Hormones (Athens), 2025, 24(1): 217-229.
44. Xing M, Liu R, Liu X, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol, 2014, 32(25): 2718-2726.
45. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid Cancer. Thyroid, 2016, 26(1): 1-133.
46. Liu J, Gao W, Zheng X, et al. Molecular testing stratifies the risk of structural recurrence in high risk differentiated thyroid cancer: a retrospective cohort study. Front Endocrinol (Lausanne), 2025, 16: 1508404. doi: 10.3389/fendo.2025.1508404.
47. 廣東省醫學教育協會甲狀腺專業委員會, 廣東省基層醫藥學會細胞病理與分子診斷專業委員會. 甲狀腺癌RET基因檢測與臨床應用專家共識 (2021版). 中華普通外科學文獻 (電子版), 2022, 16(1): 1-8.
48. 中國醫師協會外科醫師分會甲狀腺外科醫師委員會, 中國抗癌協會甲狀腺癌專業委員會, 中國研究型醫院學會甲狀腺疾病專業委員會. 甲狀腺髓樣癌診斷與治療中國專家共識 (2020版). 中國實用外科雜志, 2020, 40(9): 1012-1020.
49. Wells SA, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid, 2015, 25(6): 567-610.
50. Castinetti F, Waguespack SG, Machens A, et al. Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study. Lancet Diabetes Endocrinol, 2019, 7(3): 213-220.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Progress in the application of molecular testing in the diagnosis and treatment of thyroid cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content